Kerri Fitzgerald

DocwireNews

BEVZ92 is a biosimilar agent in development for the reference agent bevacizumab. Preclinical and in vitro studies suggest that the two products have similar physicochemical and functional properties. A study published in <a href="https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30269-3/fulltext">The Lancet Gastroenterology and Hepatology</a> found that the biosimilar and reference product are pharmacokinetically bioequivalent and have no appreciable differences in efficacy, immunogenicity, and safety profiles as first-line treatment in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or fluorouracil, leucovorin, and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (CRC).The randomized, open-label trial included adult patients with metastatic CRC with at least one measurable non-irradiated lesion for which first-line chemotherapy was indicated. Patients were included from 15 centers in Argentina, Brazil, India, Spain, and Ukraine. The researchers included patients who had an Eastern Cooperative Oncology Group performance status score &le;2, had not received previous treatment for advanced disease, and whose bone marrow, hepatic, renal, and coagulation markers were all within normal ranges.A total of 142 patients were randomized 1:1 to receive BEVZ92 (n=71) or reference bevacizumab 5 mg/kg on day one of each cycle every 2 weeks (n=71) in combination with FOLFOX or FOLFIRI. Two patients in the BEVZ92 did not receive treatment: one withdrew consent and the other had a serious intestinal obstruction before starting treatment.Bioequivalence was established if the 90% confidence intervals (Cis) for the ratio of BEVZ92 to reference bevacizumab of the geometric means for area under the curve0-336h (AUC) and AUCss were within the acceptance interval of 80&ndash;125%. In the BEVZ92 cohort, the geometric mean ratio of AUC0-336h was 99.4% (90% CI = 90.5-109.0) and AUCss was 100% (90% CI, 90.2-112.0).The objective response rate was similar between the BEVZ92 and bevacizumab groups (n=35; 49% vs. n=40; 56%), as was the clinical benefit (n=62; 87% vs. n=65; 92%). The median progression-free survival was also similar: 10.8 months (95% CI, 7.4-11.5) versus 11.1 months (95% CI, 8.0-12.8), respectively.The researchers observed no relevant differences between the safety profiles of the two study treatments. Neutropenia was the most common grade 3 or 4 adverse event (AE) in the BEVZ92 (n=14; 20%) and bevacizumab (n=19; 27%) groups. Serious AEs occurred in 19 patients (28%) in the BEVZ92 group and 21 patients (30%) in the bevacizumab group.Two patients died from treatment-related serious AEs, including a sudden death in the BEVZ92 group and a serious large intestinal perforation in the bevacizumab group. Anti-drug antibodies were reported in two patients in the BEVZ92 group and one in the bevacizumab group.

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Study Finds Biosimilar Bevacizumab Is Bioequivalent to Reference Agent

Oncology

BEVZ92 is a biosimilar agent in development for the reference agent bevacizumab. Preclinical and in vitro studies suggest that the two products have similar physicochemical ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe